| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥588.1B | ¥581.3B | +1.2% |
| Operating Income | ¥13.2B | ¥21.7B | -39.1% |
| Ordinary Income | ¥28.0B | ¥30.0B | -6.7% |
| Net Income | ¥28.4B | ¥19.9B | +42.6% |
| ROE | 2.1% | 1.6% | - |
FY2026 Q3 results: Revenue 588.1B yen (YoY +1.2%), Operating Income 13.2B yen (-39.1%), Ordinary Income 28.0B yen (-6.7%), Net Income 28.4B yen (+42.6%). Revenue remained essentially flat with a marginal increase, while operating profit declined sharply by 8.5B yen due to a combination of gross margin compression of 50bp to 32.5% and SG&A expense ratio deterioration of approximately 90bp to 30.2%, resulting in operating margin falling to 2.24% from 3.73% prior year. The ordinary profit decline was cushioned by non-operating income including dividend income of 13.0B yen and foreign exchange gains of 0.8B yen, bringing ordinary margin to 4.75%. Net income increased substantially driven by extraordinary gains from investment securities sales totaling 13.3B yen, lifting net margin to 4.83% from 3.43% prior year. This represents a revenue up/profit down pattern at the operating level, transitioning to revenue up/profit up at the net income level due entirely to non-recurring gains. The balance sheet expanded with total assets reaching 1,767.7B yen and equity 1,344.1B yen, as investment securities increased 182.5B yen to 689.7B yen (39% of total assets) and short-term borrowings surged 36.7B yen to 85.3B yen, while cash declined 61.0B yen to 149.6B yen.
Revenue increased 1.2% YoY to 588.1B yen, driven primarily by recovery in Healthcare market sales in Europe, North America and China where both diagnostic and endoscopy products performed well at 105.8% of prior year. However, this was largely offset by weakness in Business & Professional markets due to European economic stagnation, with segment sales declining to 87.4% of prior year, particularly in Germany. The Creative Work segment also underperformed at 95.0% of prior year as European demand recovery lagged, while Vessel & Safety segment remained flat at 99.6% due to postponement of air traffic control projects despite strength in marine and defense applications. Amusement maintained 102.4% of prior year despite ongoing industry contraction.
Gross profit margin compressed 50bp to 32.5%, indicating pricing pressure and unfavorable product mix shifts. Operating profit declined 39.1% to 13.2B yen as SG&A expenses grew 4.4% faster than the 1.2% revenue growth, with SG&A ratio rising approximately 90bp. The SG&A increase was primarily driven by wage increases implemented in June (+5%) and October (+1.5%), new technology building related expenses following April 2025 completion, and expanded sales activities in India and Middle East markets. This resulted in negative operating leverage with operating margin falling 149bp to 2.24%.
Ordinary income declined 6.7% to 28.0B yen, significantly outperforming the operating profit decline due to non-operating income contributions. Dividend income of 13.0B yen from the expanding investment securities portfolio and foreign exchange gains of 0.8B yen provided material support. The gap between operating and ordinary income narrowed the decline to 41bp at the ordinary margin level (4.75%).
Net income increased 42.6% to 28.4B yen driven by extraordinary gains. Investment securities sales generated 13.3B yen in gains, representing a non-recurring factor that fundamentally altered the profit trajectory. This 13.3B yen gain represents 2.3% of revenue and 46.8% of net income, highlighting substantial dependency on non-operating items.
Full-year guidance was revised downward to revenue 790B yen (-1.9% YoY), operating income 14B yen (-62.2% YoY), ordinary income 29B yen (-36.3% YoY), and net income 32B yen. Q4 guidance embeds non-recurring charges including approximately 4B yen inventory write-down for legacy B&P products due to slow new model transitions, 2B yen in manufacturing execution system disposal losses, and 1.5B yen impairment loss on European sales subsidiary. Additionally, Q4 guidance includes approximately 9.5B yen in investment securities sale gains.
This represents a revenue up/profit down pattern at the operating level, with operating performance deterioration masked at the net income level by substantial non-recurring gains. The material gap of 14.8B yen between ordinary income (28.0B) and operating income (13.2B) reflects structural dependency on investment portfolio income, while the additional 0.4B yen step-up to net income was enabled purely by asset monetization. Earnings quality concerns arise from the divergence between deteriorating core business profitability and artificially elevated net income.
Business & Professional segment recorded revenue of 281.8B yen (87.4% of prior year) with operating profit declining significantly. This core business segment, representing the largest share of group revenue, was materially impacted by European economic stagnation, particularly in the German market. Sales of new products failed to gain sufficient traction while legacy product inventory accumulated, leading to planned inventory valuation losses of approximately 4B yen in Q4. Operating margin in this segment deteriorated due to both revenue decline and fixed cost burden.
Healthcare segment generated revenue of 170.6B yen (105.8% of prior year), showing recovery momentum with strong sales in Europe, North America and China for both diagnostic and endoscopy applications. However, Japanese market weakened due to deteriorating hospital financial conditions suppressing capital equipment investments. Despite revenue growth, segment profitability was constrained by the overall SG&A expense increase affecting all segments.
Creative Work segment posted revenue of 52.3B yen (95.0% of prior year), pressured by delayed European demand recovery. North America and Japan showed resilience in video production applications, but were insufficient to offset European weakness. Segment margins faced pressure from both top-line decline and fixed cost absorption challenges.
Vessel & Safety segment recorded revenue of 44.2B yen (99.6% of prior year), maintaining prior year levels. Strong performance in marine and defense applications offset postponement of air traffic control projects which shifted revenue recognition to later periods.
Amusement segment achieved revenue of 24.1B yen (102.4% of prior year), maintaining sales levels despite ongoing structural contraction in the pachinko industry.
Other segment including contract software development grew to 15.0B yen (119% of prior year).
The core Business & Professional segment's 12.6% revenue decline was the primary driver of consolidated operating profit deterioration, with Healthcare segment growth and other segment contributions insufficient to offset this weakness. Operating profit decline was concentrated in B&P due to both revenue loss and negative operating leverage from fixed SG&A expenses.
Profitability: ROE 2.1% (prior year 1.6%), ROA 1.6%, Operating Margin 2.24% (prior year 3.73%), Ordinary Margin 4.75% (prior year 5.16%), Net Margin 4.83% (prior year 3.43%). ROE of 2.1% significantly underperforms the company's capital cost and reflects weak asset utilization with asset turnover of 0.33x. ROIC calculated as NOPAT divided by invested capital stands at approximately 0.7%, indicating capital productivity well below acceptable levels and signaling room for improvement in both operating profitability and capital efficiency.
Cash Quality: The divergence between operating performance and net income raises earnings quality concerns. While net income reached 28.4B yen, this was substantially supported by non-operating dividend income of 13.0B yen and extraordinary gains of 13.3B yen, together representing 92.6% of reported net income. Without detailed cash flow statements, working capital trends show inventory increasing 41.3B yen while accounts payable also expanded, suggesting cash absorption in operations.
Investment: Fixed assets increased 212.8B yen to 983.3B yen, driven primarily by the new technology building completion in April 2025. Investment securities expanded 182.5B yen to 689.7B yen (39% of total assets), reflecting both market value appreciation and strategic accumulation. This substantial investment base contrasts sharply with ROIC of 0.7%, indicating capital is not generating adequate returns. The ratio of investment securities to total assets at 39% is exceptionally high for a manufacturing company and exposes the balance sheet to equity market volatility.
Financial Health: Equity Ratio 76.0% (prior year 78.8%), Current Ratio 360.7%, Quick Ratio 280.7%. Financial structure remains highly conservative with minimal leverage. Interest-bearing debt totals 92.2B yen, of which 85.3B yen (92.5%) is short-term borrowings. Cash and deposits stand at 149.6B yen, providing cash coverage of short-term debt at 1.75x. Despite the short-term concentration of debt, liquidity metrics remain extremely healthy. Interest expense of 1.54B yen results in interest coverage ratio of 8.56x based on operating profit, though this has declined from higher prior year levels due to operating profit deterioration.
Operating cash flow analysis is constrained by limited data, but profit structure provides significant insights. Net income of 28.4B yen includes 13.3B yen in non-cash investment securities gains (reclassified in cash flow from investing activities) and 13.0B yen in dividend income (cash inflow in operating activities). The core operating profit of 13.2B yen represents the actual earnings power from business operations, suggesting underlying cash generation from operations is significantly weaker than headline net income suggests.
Working capital movements show inventory increasing 41.3B yen primarily in raw materials, indicating either demand shortfalls requiring production adjustments or strategic stockpiling. Accounts receivable declined marginally while accounts payable increased, providing modest working capital relief. The planned 4B yen inventory write-down in Q4 for B&P legacy products confirms excess inventory represents a cash flow and profitability headwind.
Investing cash flow shows substantial activity with fixed assets increasing 212.8B yen (technology building construction) and investment securities expanding 182.5B yen. Cash and deposits declined 61.0B yen despite investment securities sales of 13.3B yen, indicating net cash outflows for capital investment and portfolio accumulation significantly exceeded operating cash generation.
Financing cash flow included short-term borrowing increases of 36.7B yen to fund working capital and investment needs, while dividends consumed cash at an annualized rate exceeding net income given the calculated payout ratio of 234.6%.
Free cash flow is structurally negative given weak operating profit generation of 13.2B yen against capital expenditure likely exceeding 20B yen (inferred from fixed asset increase). Cash generation quality warrants monitoring as the company relies on investment portfolio monetization and increased borrowings rather than operating cash flow to fund investments and dividends.
Earnings quality presents significant concerns due to material divergence between operating and net income. Operating income of 13.2B yen represents core business profitability, while net income of 28.4B yen was artificially elevated by non-recurring and non-operating items.
Ordinary vs Net Income: The 14.8B yen gap between ordinary income (28.0B) and operating income (13.2B) was driven by dividend income of 13.0B yen from the investment securities portfolio and foreign exchange gains of 0.8B yen. These items recur but are not tied to core monitor manufacturing and sales operations. The additional 0.4B yen step-up from ordinary to net income resulted from extraordinary gains of 13.3B yen in investment securities sales, offset by minimal extraordinary losses.
Non-recurring items materiality: Investment securities sale gains of 13.3B yen represent 2.3% of revenue and 46.8% of net income, clearly material. Q4 guidance includes additional 9.5B yen in such gains plus 7.5B yen in one-time charges (4B inventory write-down, 2B disposal loss, 1.5B impairment), indicating full-year net income is substantially shaped by non-recurring items.
Accruals and cash backing: While detailed operating cash flow data is unavailable, the profit structure strongly suggests earnings quality concerns. Normalized earnings excluding investment securities gains would approximate 15B yen, less than the reported 28.4B yen. The company's guidance normalization to 55 yen annual dividend (from effective 157.5 yen rate in current period) acknowledges that current net income levels are unsustainable.
Sustainability assessment: Core operating earnings power has deteriorated with operating margin falling to 2.24%. Excluding investment portfolio contributions, ordinary income would approximate operating income levels, revealing the true business profitability. The 234.6% payout ratio calculated on headline net income confirms dividends are not supported by recurring earnings. Management's stated intent to normalize dividends to 55 yen and align with sustainable profit levels is appropriate, but highlights that FY2026 earnings substantially overstate recurring profitability.
Full-year guidance: Revenue 790B yen (original 850B yen, revised down 60B yen or 7.1%), Operating Income 14B yen (original 48B yen, revised down 34B yen or 70.8%), Ordinary Income 29B yen (original 45B yen, revised down 16B yen or 35.6%), Net Income 32B yen (original 32B yen, maintained). Annual dividend guidance revised to 55 yen (interim 0 yen paid, year-end 55 yen) from effective 157.5 yen in current period.
Progress rate vs full-year guidance: Q3 cumulative represents 74.4% of revenue guidance (standard Q3 target: 75%), 94.3% of operating income guidance, 96.6% of ordinary income guidance, and 88.8% of net income guidance. Operating income and ordinary income are tracking significantly ahead of proportional pace, indicating Q4 is expected to face substantial headwinds.
Revision drivers: Revenue downgrade of 60B yen reflects worse-than-expected European economic conditions impacting B&P segment sales (original assumption of recovery failed to materialize) and Creative Work segment demand remaining weak. Operating income downgrade of 34B yen results from both revenue shortfall and higher-than-planned SG&A expenses (wage increases, technology building costs, overseas expansion). The 70.8% operating income cut is severe and reflects fundamental deterioration in core business profitability.
Q4 embedded assumptions: Q4 implies revenue of approximately 202B yen, operating income of approximately 0.9B yen, ordinary income of approximately 1B yen, and net income of approximately 3.6B yen. The near-zero operating profit guidance for Q4 incorporates planned charges including 4B yen inventory write-down for B&P legacy products, 2B yen manufacturing system disposal loss, and 1.5B yen impairment of European subsidiary. Offsetting these charges, Q4 guidance embeds approximately 9.5B yen in investment securities sale gains to support net income.
Guidance credibility: The revised guidance appears realistic given Q3 run-rate and explicitly disclosed Q4 one-time items. However, achievement depends heavily on realization of planned investment securities sales (9.5B yen) and accurate estimation of restructuring charges. Operating performance guidance of near-zero Q4 operating profit reflects management's conservative assessment of business conditions. The substantial reliance on asset monetization to achieve net income targets underscores weak underlying earnings power.
Dividend policy shows significant recalibration. Interim dividend of 105 yen was paid, with year-end dividend guidance of 52.5 yen, totaling 157.5 yen for the period. This represents a payout ratio of approximately 234.6% against reported net income of 28.4B yen per share equivalent, clearly unsustainable relative to earnings.
However, management has announced normalization of dividend policy, with full-year guidance revised to 55 yen annual dividend (year-end 55 yen payment only). This 55 yen level represents management's assessment of sustainable dividend aligned with recurring profitability, implicitly acknowledging that FY2026 net income of 28.4B yen (inflated by 13.3B yen investment securities gains) overstates sustainable earnings power.
At 55 yen annual dividend against full-year net income guidance of 32B yen, the normalized payout ratio would approximate 68-70%, still elevated but more sustainable. Management commentary emphasizes returning to dividend levels consistent with underlying profit generation capacity.
No share buyback programs are disclosed or planned. Total return ratio equals payout ratio in absence of buybacks.
Sustainability assessment: Current period's 157.5 yen effective dividend rate is not sustainable given deteriorating operating profitability and dependency on non-recurring gains. The planned normalization to 55 yen annual dividend is prudent and necessary. Even at 55 yen, sustainability depends on recovery of operating profitability from current 2.24% margin to historical levels above 5%, and improvement in ROIC from 0.7% to levels exceeding capital cost. With cash reserves of 149.6B yen and low leverage, near-term dividend payment capacity exists, but medium-term sustainability requires operating performance improvement. The effective dividend cut from 157.5 yen to 55 yen (65% reduction) appropriately aligns returns with recurring earnings capacity.
Near-term: Q4 inventory optimization program including 4B yen write-down of B&P legacy products and acceleration of new product transitions in European markets. Completion of manufacturing execution system replacement with 2B yen disposal loss, expected to drive future operational efficiency gains. Realization of approximately 9.5B yen additional investment securities sales in Q4 to support net income. April 2026 launch of mitococa Edge V3 AI edge computer incorporating JR West Japan's "mitococa AI" image analysis platform, representing entry into railway AI infrastructure market. Progressive contribution from new technology building commissioned April 2025, enabling advanced R&D and production capabilities.
Long-term: Expansion in India and Middle East markets where sales infrastructure investments are underway, targeting 3-5 year revenue contribution. Healthcare segment growth trajectory supported by aging demographics in developed markets and increasing adoption of 4K surgical displays (CuratOR EX2742 27-inch 4K model launched October 2025). Recovery of European B&P market demand as economic conditions stabilize, with new environmentally advanced products gaining share. Vessel & Safety segment order book conversion as postponed air traffic control projects materialize in FY2027-2028. Operating margin recovery toward 5%+ levels through SG&A efficiency gains post-investment cycle and improved product mix. ROIC improvement toward 5%+ through combination of operating margin expansion and optimization of investment securities portfolio weighting relative to operating assets.
Industry Position (Reference - Proprietary Analysis):
Profitability: Operating Margin 2.2% vs. industry median 7.3% (IQR: 4.6%-12.0%, n=65). EIZO's operating margin significantly underperforms the manufacturing sector median by 5.1 percentage points, placing the company in the bottom quartile and below the 25th percentile threshold of 4.6%. This substantial gap reflects both gross margin pressure and SG&A expense burden that industry peers have better managed. Net Profit Margin 4.8% vs. industry median 5.4% (IQR: 3.5%-8.9%, n=65). Net margin sits slightly below median, indicating investment portfolio income partially compensates for weak operating profitability but insufficiently to reach industry median performance. ROE 2.1% vs. industry median 4.9% (IQR: 2.8%-8.2%, n=65). EIZO's ROE ranks in the bottom quartile, below even the 25th percentile of 2.8%, reflecting poor capital productivity. ROA 1.6% vs. industry median 3.3% (IQR: 1.8%-5.1%, n=65). Return on assets similarly underperforms, indicating weak asset utilization particularly given high investment securities weighting.
Growth: Revenue Growth YoY 1.2% vs. industry median 2.8% (IQR: -0.9%-7.9%, n=65). Revenue growth trails industry median by 1.6 percentage points, positioning near the lower quartile threshold. While not in the bottom quartile, growth momentum is below manufacturing sector average.
Financial Health: Equity Ratio 76.0% vs. industry median 63.9% (IQR: 51.5%-72.3%, n=65). EIZO maintains equity ratio well above industry median and exceeding the 75th percentile, reflecting conservative capital structure with minimal leverage. Current Ratio 360.7% vs. industry median 267% (IQR: 200%-356%, n=65). Liquidity significantly exceeds industry norms, positioning above the 75th percentile and indicating substantial financial flexibility. Net Debt/EBITDA: EIZO maintains net cash position (cash 149.6B yen exceeds interest-bearing debt 92.2B yen) vs. industry median of -1.11, placing the company among the strongest balance sheet positions in the sector.
Summary: EIZO demonstrates superior financial health and liquidity relative to manufacturing peers, but severely underperforms on profitability and capital efficiency metrics. The bottom-quartile ROE and operating margin indicate fundamental operational challenges that conservative balance sheet management cannot offset. Revenue growth below industry median suggests competitive positioning challenges in core markets.
(Industry: Manufacturing sector, N=65 companies, Comparison period: FY2025 Q3, Source: Proprietary analysis)
Operating leverage deterioration risk: SG&A expenses grew 4.4% against revenue growth of 1.2%, with operating margin compressing 149bp to 2.24%. Fixed cost burden from wage increases (June +5%, October +1.5%), new technology building operational expenses, and overseas market expansion costs total approximately 4-5B yen annually. If revenue growth remains subdued at 1-2% levels, operating margin faces risk of further compression toward 1-1.5% range or potential operating losses. The structural SG&A increase is largely irreversible in the near term, making top-line growth the critical variable for margin recovery.
European market dependency and cyclical exposure risk: Business & Professional segment revenue declined 12.6% in Q3 due to European economic stagnation, particularly in Germany. This core segment represents the largest revenue contribution, and sustained European weakness into FY2027 could drive additional 10-15% revenue decline in B&P, translating to 30-40B yen consolidated revenue headwind. Healthcare segment also showed weakness in developed markets as hospital financial conditions deteriorate. With geographic concentration in Europe across multiple segments, macroeconomic conditions in the region represent the single largest demand risk, particularly if recession materializes.
Investment securities portfolio volatility risk: Investment securities of 689.7B yen represent 39% of total assets and 51.3% of equity, with valuation gains of approximately 130B yen in other comprehensive income. A 20% equity market correction would trigger approximately 138B yen in portfolio value decline, exceeding annual revenue and potentially reducing equity ratio from 76% toward 68-70%. While this remains financially healthy, the psychological and accounting impact would be material. Additionally, dividend income of 13.0B yen and realized gains of 13.3B yen in Q3 demonstrate structural dependency on portfolio performance to support consolidated profitability. Sustained equity market weakness would simultaneously reduce portfolio income, impair balance sheet, and eliminate the asset monetization option currently used to support net income and dividends.
Structural profitability deterioration masked by non-recurring gains: Operating margin declined 149bp to 2.24%, placing EIZO 5.1 percentage points below manufacturing sector median of 7.3% and in the bottom quartile of industry peers. The deterioration was driven by both 50bp gross margin compression (indicating pricing power and product mix challenges) and 90bp SG&A ratio expansion (reflecting fixed cost burden outpacing revenue growth). Despite this operating weakness, net income increased 42.6% due entirely to 13.3B yen investment securities sale gains representing 46.8% of net income. Management's guidance embeds additional 9.5B yen Q4 gains plus 7.5B yen in restructuring charges, confirming full-year earnings are substantially shaped by non-recurring items. The company's own normalization of dividends from effective 157.5 yen to 55 yen (65% reduction) explicitly acknowledges that headline net income overstates sustainable profitability by approximately 2-3x. Core earnings power excluding portfolio contributions approximates 15B yen annually, implying true P/E multiples are 2-3x headline ratios and sustainable ROE closer to 1.0-1.5% rather than reported 2.1%.
Capital efficiency crisis requiring strategic portfolio rebalancing: ROIC of 0.7% and ROE of 2.1% rank in the bottom quartile of manufacturing peers (industry median ROE 4.9%), indicating capital is actively destroying value relative to opportunity cost. The root cause is dual: weak operating profitability (operating margin 2.24%) and distorted capital allocation with investment securities representing 39% of assets. These marketable securities generate dividend income of 13B yen (approximately 1.9% yield) but contributed 182.5B yen of the 190B yen asset expansion, absorbing virtually all growth capital. Meanwhile, core monitor business with 588B yen revenue generates only 13.2B yen operating profit (2.24% margin), producing ROIC well below 5% threshold for value creation. The portfolio allocation raises fundamental questions about business model and management priorities: whether EIZO is a monitor manufacturer with investment portfolio, or investment company with monitor manufacturing operations. Return to acceptable capital efficiency requires either dramatic operating margin improvement to 6-8% levels through restructuring, or strategic reallocation of investment securities toward operating assets or return to shareholders.
Dividend sustainability dependent on operating turnaround timeline: Management's dividend normalization to 55 yen from effective 157.5 yen acknowledges current earnings are unsustainable, but even the 55 yen level implies 68-70% payout ratio against normalized earnings that may not materialize. With operating margin at 2.24% and full-year operating income guidance of only 14B yen (0.6B yen per quarter), the business barely generates operating profit to cover interest expense of 1.54B yen. Ordinary income of 28-29B yen relies structurally on 13B yen portfolio dividend income, meaning core business contributes only 15-16B yen to ordinary income. At 55 yen dividend requiring approximately 22-24B yen payout against 15-16B yen core ordinary income, the dividend remains dependent on portfolio contributions. Near-term coverage exists given 149.6B yen cash reserves and ability to monetize securities, but medium-term sustainability beyond 2-3 years requires operating margin recovery toward 5% levels and operating income reaching 40-50B yen. The investment decision framework must therefore assess probability and timeline of operating turnaround: if margin recovery materializes within 2 years, 55 yen dividend is sustainable; if structural profitability remains impaired beyond 3 years, further dividend reduction becomes probable despite strong balance sheet.
This report was automatically generated by AI integrating XBRL earnings data and PDF presentation materials as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.